Catalyst Pharmaceuticals, Inc. ( CPRX ) NASDAQ Capital Market

Cena: 21.05 ( 2.38% )

Aktualizacja 08-22 21:58
NASDAQ Capital Market
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Catalyst Pharmaceuticals, Inc., komercyjna firma biofarmaceutyczna, koncentruje się na rozwoju i komercjalizowaniu terapii u osób z rzadkimi wyniszczającymi, przewlekłymi chorobami neuromięśniowymi i neurologicznymi w Stanach Zjednoczonych. Oferuje Firdapse, tabletki fosforanowe amifamprydyny do leczenia pacjentów z zespołem miastenicznym Lambert-Eaton (LEM); i Ruzurgi do leczenia pacjentów z lemami pediatrycznymi. Firma rozwija również FIRDapse do leczenia przeciwciała MKKUS Myasthenia Gravis i kręgosłupa atrofii mięśniowej typu 3, a także do leczenia neuropatii dziedzicznej z odpowiedzialnością za porażenie ciśnieniowe. Ma umowy licencyjne z Biomarin Pharmaceutical Inc.; oraz umowa o współpracy i licencji z Endo Ventures Limited w celu opracowania i komercjalizacji ogólnych tabletek Sabril. Firma była wcześniej znana jako Catalyst Pharmaceutical Partners, Inc. i zmieniła nazwę na Catalyst Pharmaceuticals, Inc. w maju 2015 r. Catalyst Pharmaceuticals, Inc. został założony w 2002 roku i ma siedzibę w Coral Gables na Florydzie.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 167
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 84.7718
Ilość akcji: Brak danych
Debiut giełdowy: 2006-11-08
WWW: https://www.catalystpharma.com
CEO: Mr. Richard John Daly M.B.A.
Adres: 355 Alhambra Circle
Siedziba: 33134 Coral Gables
ISIN: US14888U1016
Wskaźniki finansowe
Kapitalizacja (USD) 2 576 330 550
Aktywa: 772 010 000
Cena: 21.05
Wskaźnik Altman Z-Score: 16.6
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 12.8
Ilość akcji w obrocie: 85%
Średni wolumen: 1 374 872
Ilość akcji 122 391 000
Wskaźniki finansowe
Przychody TTM 460 482 000
Zobowiązania: 111 069 000
Przedział 52 tyg.: 19.0 - 26.58
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 1.6
P/E branży: 28.3
Beta: 0.755
Raport okresowy: 2025-11-05
WWW: https://www.catalystpharma.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Steven R. Miller Ph.D. Executive Vice President, Chief Operating Officer & Chief Scientific Officer 884 700 1962
Dr. Gary Ingenito M.D., Ph.D. Chief Medical & Regulatory Officer 811 386 1956
Mr. Jeffrey Del Carmen Executive Vice President & Chief Commercial Officer 799 819 1971
Mr. Richard John Daly M.B.A. President, Chief Executive Officer & Director 68 125 1961
Dr. Preethi Sundaram Ph.D. Chief Strategy Officer 511 255 1976
Mr. Brian Elsbernd J.D. Chief Compliance Officer & Chief Legal Officer 311 416 1964
Mr. Pete Curry Sr. Vice President of Sales 0 0
Mr. Michael W. Kalb CPA Executive Vice President, Treasurer & Chief Financial Officer 0 1971
Ms. Mary Coleman Vice President & Head of Investor Relations 0 0
Dr. Stanley Iyadurai M.D., Ph.D. Senior Vice President of Medical Affairs & Drug Discovery 0 0
Lista ETF z ekspozycją na akcje Catalyst Pharmaceuticals, Inc.
Symbol ETF Ilość akcji Wartość
IJR 6 828 967 145 661 876
IWM 2 765 981 58 998 374
AVUV 1 586 653 33 763 975
XBI 1 159 927 24 110 370
IWO 1 012 059 21 587 219
IJT 998 319 21 294 151
SPSM 992 555 21 173 925
CALF 600 004 12 798 085
VTWO 589 546 12 793 148
SLYG 558 585 11 888 615
SCHA 540 448 11 381 284
VIOO 379 615 8 237 645
XSMO 372 240 7 921 267
JSMD 371 105 7 915 670
VHT 359 867 7 809 113
DFAS 286 301 6 106 800
PBE 245 155 5 216 898
DFAC 189 355 4 038 942
AVSC 188 866 4 019 068
SMLF 180 769 3 855 808
R2SC.L 176 178 2 841 006
R2US.L 176 178 3 749 067
ZPRR.DE 176 178 3 283 058
IUS3.DE 167 236 3 120 538
IDP6.L 167 236 3 567 145
ISP6.L 167 236 2 699 900
2B78.DE 149 366 2 787 093
HEAL.L 149 366 3 185 977
DRDR.L 149 366 2 411 402
VIOG 136 564 2 963 438
ITOT 134 924 2 877 928
FESM 127 942 2 661 193
XSHQ 126 729 2 696 793
USVM 122 882 2 621 073
PSCH 109 928 2 339 267
LABU 108 790 2 320 490
VTWG 102 565 2 225 660
FSMD 86 757 1 804 545
SFLO 85 821 1 830 561
DFUV 80 560 1 718 344
FYC 78 894 1 648 884
GSSC 77 403 1 673 839
PTH 72 111 1 534 522
XRSG.L 69 909 112 998 116
XRSU.L 69 909 1 491 153
XRS2.DE 69 909 1 305 803
2B77.DE 67 793 1 264 977
AGED.L 67 793 1 446 018
AGES.L 67 793 1 094 462
SXRG.DE 64 254 1 198 946
CUSS.L 64 254 1 370 538
CUS1.L 64 254 1 037 333
CSUSS.MI 64 254 1 198 946
SCHB 63 536 1 346 954
JPSE 59 734 1 274 126
EES 59 634 1 271 993
RSSL 59 083 1 260 240
ESML 59 058 1 256 754
PSC 57 964 1 236 372
CLSE 54 318 1 158 602
RZG 49 588 1 055 232
FHLC 49 127 1 021 841
FYX 47 283 988 214
VFMO 46 992 1 019 726
PRFZ 46 451 988 477
AVUS 44 252 941 682
BBSC 40 722 868 600
IJR.AX 40 469 1 333 058
XS5E.DE 40 468 755 887
XSPX.L 40 468 65 410 965
XSPU.L 40 468 863 180
D5BM.DE 40 468 755 887
XS5G.L 40 468 654 109
XSXD.L 40 468 863 180
DFAT 39 450 841 468
FDLS 38 860 828 883
ONEQ 35 438 737 110
IWV 32 108 684 854
RWJ 22 612 481 183
DFAU 20 708 441 701
ISCG 20 347 434 005
OMFS 20 204 429 941
XSU.TO 19 938 585 989
ETHO 18 629 397 356
SPTM 18 149 386 868
QVMS 17 893 380 763
VAMO 17 379 370 694
ROSC 14 830 315 582
AFSM 14 280 298 452
VFQY 13 508 293 123
VFMF 13 391 290 584
CAFG 12 318 262 742
UWM 11 717 249 923
MNTL 11 352 241 570
FAD 10 179 212 741
DCOR 10 078 214 963
URTY 9 698 206 858
SMLV 9 507 204 545
XJR 9 061 192 818
FLQS 8 976 191 009
VTHR 8 948 194 171
TILT 8 304 177 124
ZPRV.DE 6 410 104 050
USSC.L 6 410 118 819
IBRN 5 548 118 338
AVSU 5 270 112 145
HELX 5 209 110 847
ISCB 5 207 111 060
SPGM 4 718 100 620
XUU.TO 4 695 137 986
FTXH 4 694 98 104
SQLV 4 692 99 845
XSMC.TO 4 039 118 713
XSMH.TO 3 736 109 808
STXK 3 494 74 527
DXUV 3 396 72 436
CBUG.DE 2 794 52 142
EWSA.AS 2 794 59 605
SAA 2 114 45 091
VMO.TO 1 856 54 955
CSA 1 616 36 521
GRPZ 1 551 33 005
ESIX 888 19 004
USFM.L 797 16 961
USUE.DE 797 16 961
XBAL.TO 781 22 954
XUH.TO 693 14 749
VLU 564 12 070
CSF 502 11 345
MMTM 425 9 025
EBIT 259 5 511
HDG 140 2 986
XTR.TO 28 597
SC0K.DE 0 205 412
USML.L 0 351 350
PZW.TO 0 4 630
RTYS.L 0 234 435
Wiadomości dla Catalyst Pharmaceuticals, Inc.
Tytuł Treść Źródło Aktualizacja Link
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joel Beatty - Baird Charles Duncan - Cantor Fitzgerald Rohan Matur - Oppenheimer & Co. Inc. Jason Gerberry - Bank of America Global Research Felix Ampomah - Stephens & Co. Operator Good day everyone, and welcome to the Catalyst Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-05-08 16:02:12 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales. zacks.com 2025-05-08 16:00:50 Czytaj oryginał (ang.)
Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-05-08 00:05:52 Czytaj oryginał (ang.)
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago. zacks.com 2025-05-07 23:31:01 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year  of Between $545 Million and $565 Million Strengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million  and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2025 and provided a business update. globenewswire.com 2025-05-07 20:14:00 Czytaj oryginał (ang.)
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy? Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-30 15:06:58 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. globenewswire.com 2025-04-30 12:03:00 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET globenewswire.com 2025-04-22 12:03:00 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization before the end of 2025. If approved, AGAMREE would be the first and only treatment option indicated for patients diagnosed with DMD in Canada. globenewswire.com 2025-04-08 12:06:00 Czytaj oryginał (ang.)
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared. fool.com 2025-04-03 20:50:48 Czytaj oryginał (ang.)
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? zacks.com 2025-03-28 14:36:07 Czytaj oryginał (ang.)
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily. investors.com 2025-03-27 14:21:19 Czytaj oryginał (ang.)
Strong Revenue, Drug Performance Lift Catalyst Shares Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX). fxempire.com 2025-03-26 10:12:51 Czytaj oryginał (ang.)
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. zacks.com 2025-03-25 14:10:23 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by expanding drug distribution, increasing dosages, and acquiring additional drugs, while downside risk is limited by strong cash flow and exclusivity runways. The base case is very realistic, offering an attractive asymmetric trade payoff with a potential 40% upside, despite risks associated with acquisition-dependent revenue growth. seekingalpha.com 2025-03-11 06:05:33 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 being held in Miami, Florida. globenewswire.com 2025-03-04 10:03:00 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they'll achieve a “managed and gradual” revenue decline. seekingalpha.com 2025-03-03 16:39:44 Czytaj oryginał (ang.)
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected. fool.com 2025-02-27 16:35:42 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joseph Catanzaro - Piper Sandler Joel Beatty - Baird Felix Ampomah - Stephens Operator Greetings, and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-02-27 14:29:03 Czytaj oryginał (ang.)
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. zacks.com 2025-02-27 12:10:31 Czytaj oryginał (ang.)
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-26 23:30:35 Czytaj oryginał (ang.)
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago. zacks.com 2025-02-26 21:50:22 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the fourth quarter and full year 2024 and provided a business update. globenewswire.com 2025-02-26 18:13:00 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025. globenewswire.com 2025-02-12 10:03:00 Czytaj oryginał (ang.)
Catalyst Remains a Big Money Favorite Catalyst Pharmaceuticals, Inc. (CPRX) shares keep gaining on Big Money buys. fxempire.com 2025-02-07 17:56:43 Czytaj oryginał (ang.)
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point. investors.com 2025-01-31 10:00:30 Czytaj oryginał (ang.)
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2025-01-24 12:55:24 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap Companies for the year 2025. Catalyst has ranked an impressive fifth out of 100 companies on the list. globenewswire.com 2025-01-23 10:03:00 Czytaj oryginał (ang.)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com 2025-01-22 11:55:32 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS"). globenewswire.com 2025-01-21 10:19:00 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epilepsy. Detailed revenue breakdown from Q3 2024 10-Q highlights FIRDAPSE as the main revenue driver. seekingalpha.com 2025-01-13 10:30:00 Czytaj oryginał (ang.)
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035. zacks.com 2025-01-09 12:56:21 Czytaj oryginał (ang.)
Here's Why Momentum in Catalyst (CPRX) Should Keep going Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com 2025-01-09 12:01:51 Czytaj oryginał (ang.)
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2025-01-09 11:20:23 Czytaj oryginał (ang.)
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva appeared first on Investor's Business Daily. investors.com 2025-01-08 16:57:04 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 globenewswire.com 2025-01-08 14:30:00 Czytaj oryginał (ang.)
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2025-01-07 13:06:41 Czytaj oryginał (ang.)
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-24 12:51:11 Czytaj oryginał (ang.)
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2024-12-18 12:40:28 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA. globenewswire.com 2024-12-16 10:03:00 Czytaj oryginał (ang.)
Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report? Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-09 08:49:27 Czytaj oryginał (ang.)
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2024-12-02 17:26:24 Czytaj oryginał (ang.)
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2024-11-27 13:01:14 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution globenewswire.com 2024-11-25 10:03:00 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below. globenewswire.com 2024-11-19 10:03:00 Czytaj oryginał (ang.)
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2024-11-15 12:51:44 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community. globenewswire.com 2024-11-13 10:03:00 Czytaj oryginał (ang.)
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article. zacks.com 2024-11-11 10:51:11 Czytaj oryginał (ang.)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio. zacks.com 2024-11-08 10:21:31 Czytaj oryginał (ang.)
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance. zacks.com 2024-11-07 13:30:36 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Richard Daly - President and Chief Executive Officer Michael Kalb - Chief Financial Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical & Regulatory Officer Conference Call Participants Joon Lee - Truist Securities Charles Duncan - Cantor Fitzgerald Samantha Semenkow - Citi Investment Research Operator Thank you for standing by. My name is Kris and I will be your conference operator today. seekingalpha.com 2024-11-07 12:34:10 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-11-07 12:20:36 Czytaj oryginał (ang.)
Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2024-11-06 21:00:31 Czytaj oryginał (ang.)
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.24 per share a year ago. zacks.com 2024-11-06 20:26:19 Czytaj oryginał (ang.)
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update Reports Q3 2024 Total Revenues of $ 128.7 Million, Representing a 25.3 % YoY Increase globenewswire.com 2024-11-06 18:12:00 Czytaj oryginał (ang.)
CPRX vs. STVN: Which Stock Is the Better Value Option? Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com 2024-11-06 14:45:45 Czytaj oryginał (ang.)
Pick These 4 Solid Net Profit Margin Stocks to Boost Portfolio Return Pick these four top-ranked stocks, VRT, LMB, ATAT and CPRX, with solid net profit margins to enhance your portfolio returns. zacks.com 2024-10-28 12:05:29 Czytaj oryginał (ang.)